# Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

> **NCT02183701** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 715 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Losartan + Hydrochlorothiazide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02183701
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 1998-12
- **Final completion:** —
- **Target enrollment:** 715 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183701, "Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*